STOCK TITAN

LIGAND PHARMS GLUCAGON (LGNXZ) EPS by Year

LGNXZ

LIGAND PHARMS GLUCAGON earned $6.13 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $9.41 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters LIGAND PHARMS GLUCAGON has filed alongside them.

FY2025 annual
EPS (Diluted) $6.13
YoY n/m
5Y CAGR n/m
10Y CAGR -5.5%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

LGNXZ EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
EPS (Diluted)$9.41$6.13n/m-$0.22-107.5%$2.94n/m-$1.98-159.8%$3.31n/m-$0.18-100.6%$31.85+434.4%$5.96+1024.5%$0.53n/m-$0.08-100.7%$10.83+1833.9%$0.56+1.8%$0.55n/m-$0.03-106.1%$0.49

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

LGNXZ EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)$2.22+825.0%-$0.67n/m$2.18n/m$5.68n/m$0.24n/m-$2.21-146.5%-$1.68-263.1%-$0.39n/m-$2.88-2315.4%$4.75+103.9%$1.03n/m-$0.59-3050.0%

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More LIGAND PHARMS GLUCAGON financials

Frequently Asked Questions

What was LIGAND PHARMS GLUCAGON's diluted earnings per share in fiscal year 2025?

LIGAND PHARMS GLUCAGON earned $6.13 per diluted share in fiscal year 2025.

How fast is LIGAND PHARMS GLUCAGON's diluted earnings per share growing?

LIGAND PHARMS GLUCAGON (LGNXZ) reported a loss of $0.22 per diluted share in fiscal year 2024 and $6.13 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

What is LIGAND PHARMS GLUCAGON's diluted earnings per share over the last twelve months?

LIGAND PHARMS GLUCAGON (LGNXZ) reported $9.41 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, LIGAND PHARMS GLUCAGON (LGNXZ) diluted earnings per share went from $0.49 in fiscal year 2011 to $6.13 in fiscal year 2025.

LIGAND PHARMS GLUCAGON (LGNXZ) reported $2.22 in diluted earnings per share in Q2 2026. This represents an increase of 825.0% from the same quarter a year earlier.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what LIGAND PHARMS GLUCAGON (LGNXZ) reported on that line in every period on record.